# The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

> **NCT01022333** · PHASE1 · UNKNOWN · sponsor: **Women's College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Diindolylmethane (DIM)

## Key facts

- **NCT ID:** NCT01022333
- **Lead sponsor:** Women's College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2009-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022333, "The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01022333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*